DSGN Projected Dividend Yield

Design Therapeutics Inc ( NASDAQ : DSGN )

Design Therapeutics is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTAC™ molecules. The U.S. Food and Drug Administration has granted Fast Track designation to Co.'s primary Friedreich ataxia (FA) GeneTAC™ development candidate (DT-216) for the treatment of patients with FA. Co.'s second GeneTAC™ development candidate (DT-168) is an eye drop for the treatment of Fuchs Endothelial Corneal Dystrophy. Co.'s third program based on the GeneTAC™ platform is myotonic dystrophy type-1. Co. continues to develop its GeneTAC™ portfolio in preclinical studies to address other serious nucleotide repeat expansion-driven monogenic diseases.

20 YEAR PERFORMANCE RESULTS